> 50% predicted, FEV1/FEV > 75%) , coronary artery 
disease, congestive heart failure (cardiac ejection 
fraction > 50%) , active serious infection, HIV 
positivity, other malignancies besides basal cell skin 
cancer, or evidence of active CNS leukemia. 
4.11 Patients may have received prior treatment with 
chemotherapy (e.g. hydroxyurea) , interferon, 
splenectomy, or splenic irradiation [<1000 Cgy] . 
Patients who have received prior cranial-spinal 
radiation will be excluded. 
4.12 Patients must have ECOG performance status of 0 or 1. 
(see Appendix A) 
4.13 Patients must be able to give informed consent. 
In all cases of minors the protocol will be explained 
to the patient's responsible family member who then 
must give consent. 
4.14 Previously treated patients may be eligible for entry 
into the protocol at various points. Patients who have 
received interferon . therapy or chemotherapy previously 
may be entered into the protocol at the appropriate 
treatment points e.g. interferon resistant chronic 
phase patients on hydroxyurea would be eligible to 
proceed to cytoreductive treatment stem cell harvest 
and transplant. 
5.0 Treatment Plan 
Patients will be divided into two groups: Group 1: 1st 
chronic phase and, Group 2: advanced disease (accelerated 
phase, blast phase, > 1st chronic phase) 
5.1 Group 1 (patients in 1st chronic phase): Cytoreductive 
Treatment Prior to Stem Cell Harvest 
1. Interferon alpha induction : 5 x 10 6 IU/m2/day 
subcutaneously to achieve maximum clinical and 
cytogenetic response (see 13.0) (recommended 
therapy for patients who have not had prior 
treatment or have ongoing therapy with 
interferon) . 
2 . Complete Responders to Interferon : 
Patients who achieve a complete response (0-5% Ph+ 
cells) continue interferon indefinitely at the 
discretion of their referring physician. Patients 
may have marrow and peripheral blood stored 
electively at this point. In this uncommon 
[156] 
Recombinant DNA Research, Volume 16 
